Developing novel cancer therapeutics that inhibit the enzyme PKB
Submitting Institution
Institute of Cancer ResearchUnit of Assessment
Clinical MedicineSummary Impact Type
TechnologicalResearch Subject Area(s)
Biological Sciences: Biochemistry and Cell Biology
Summary of the impact
Protein kinase B (PKB), also known as AKT, is an enzyme in the PI3
kinase/mTOR intracellular signalling pathway, which is found to be
deregulated in many forms of cancer. Professor David Barford's team at the
ICR solved the crystal structure of PKB03b2 using innovative protein
engineering and licensed six international pharmaceutical companies with
reagents to enable them to begin PKB drug discovery programmes. The ICR
also initiated its own PKB drug discovery programme: two series of
inhibitors were developed that were licensed to AstraZeneca and Astex and
are now both in clinical trial. The ICR's work helped to establish PKB as
a valid cancer therapeutic target. The ICR is involved in clinical
research studies of multiple PI3 kinase and PKB inhibitors, and this
research has led to the definition of useful clinical pharmacodynamic
biomarkers.
Underpinning research
Professor David Barford (ICR faculty member, UoA5) and his team published
the results of research, conducted between 1999 and 2002, in collaboration
with a team at the Friedrich Miescher Institute, on the crystal structure
of the enzyme PKB03b2 (also known as AKT2, (Yang et al, 2002, Nat. Struct.
Biol. 9, 940-944)). PKB was known to be a key enzyme in the PI3
kinase/mTOR signalling pathway and is overexpressed, mutated and amplified
in certain cancers and as such it was a potential target for anti-cancer
drugs. Before the Barford team published the crystal structure of PKB03b2,
the development of inhibitors of PKB had been hindered by the lack of
protein structural information.
Using the Barford crystal structure information, ICR Cancer Therapeutics
teams led by Dr Michelle Garrett (ICR Faculty), Professor Paul Workman
(ICR Faculty), Dr Ian Collins (ICR Faculty) as lead chemist and Dr Suzanne
Eccles (ICR Faculty), began an in-house drug discovery research programme
in 2002, which in 2003 became a collaboration with the UK company Astex
Pharmaceuticals, and used their virtual screening technology and high
throughput crystallography technology. The programme aimed at finding ATP
competitive inhibitors of PKB.
Two fragment hits from the PKB virtual screen were elaborated using
structure-based design and chemistry based on the Barford protein
structure information. The chemistry research was a collaboration between
the ICR and Astex Pharmaceuticals with Collins taking a lead role for the
ICR, which undertook half the medicinal chemistry research on this
project. The majority of the biological research studies were undertaken
at the ICR, and these helped to validate PKB as a potentially useful
oncology target. Each of the two hits led to the identification of a lead
chemical series, and a number of publications resulted (Refs 1-4). One
chemical series (Refs 2-4) was licensed to AstraZeneca. The second series
was retained by Astex Pharmaceuticals; this chemical series is distinct
from the first as it has a broader specificity and inhibits other AGC
kinases, which could contribute to anticancer activity (Ref 1). In
particular it has potent Rho kinase activity and a biologically distinct
profile.
The ICR and its partner institution The Royal Marsden NHS Foundation
Trust (RM) has also contributed to the PKB field through its clinical
research. The first PKB inhibitor to enter the clinic was the Merck
product (MK-2206), an allosteric inhibitor; the ICR and the RM were
involved in the Phase I studies of this compound (Ref 5). The ICR led the
way in developing clinical pharmacodynamic biomarkers for monitoring
target engagement and the response of patients to PKB inhibitors (Ref 5).
These biomarkers measure if the target is being inhibited, demonstrating
`target engagement'. This research included the establishment of a novel
method for monitoring PKB target engagement in hair (eyebrow) follicles
and platelet rich plasma (PRP) as surrogate tissues, and was successfully
implemented in multiple clinical trials (ref MK2206 trial, e.g.
NCT00670488). Subsequently, both the hair follicle and PRP PD assays have
been applied to Phase I clinical trials of multiple PI3 kinase and PKB
inhibitors, including AZD5363 and AT13148, which both arose from the ICR
PKB drug discovery programme.
References to the research
All ICR authors are in bold and ICR team leaders/Faculty are in bold and
underlined.
1. Yap TA, Walton MI, Grimshaw KM, Te Poele RH, Eve PD,
Valenti MR, de Haven Brandon AK, Martins V, Zetterlund A, Heaton SP,
Heinzmann K, Jones PS, Feltell RE, Reule M, Woodhead SJ, Davies TG,
Lyons JF, Raynaud FI, Eccles SA, Workman P,
Thompson NT, Garrett MD. 2012, AT1348 Is a Novel, Oral
Multi-AGC Kinase Inhibitor with Potent Pharmacodynamic and Antitumor
Activity, Clin Cancer Res. 18, 3912-3923. (http://dx.doi.org/10.1158/1078-0432.CCR-11-3313)
2. Caldwell JJ, Davies TG, Donald A, McHardy T, Rowlands MG,
Aherne GW, Hunter LK, Taylor K, Ruddle R, Raynaud FI, Verdonk M, Workman
P, Garrett MD, Collins I. 2008, Identification
of 4-(4-aminopiperidin-1-yl)-7H-pyrrolo[2,3-d]pyrimidines as
Selective Inhibitors of Protein Kinase B through Fragment Elaboration, J
Med Chem. 51 (7), 2147-2157. (http://dx.doi.org/10.1021/jm701437d)
3. Yap TA, Walton MI, Hunter LK, Valenti M, de Haven Brandon A, Eve
PD, Ruddle R, Heaton SP, Henley A, Pickard L, Vijayaraghavan G, Caldwell
JJ, Thompson NT, Aherne W, Raynaud FI, Eccles SA, Workman
P, Collins I, Garrett MD. 2011, Preclinical
Pharmacology, Antitumor Activity, and Development of Pharmacodynamic
Markers for the Novel, Potent AKT Inhibitor CCT128930, Mol Cancer Ther.
10, 360-371. (http://dx.doi.org/10.1158/1535-7163.MCT-10-0760)
4. McHardy T, Caldwell JJ, Cheung KM, Hunter LJ, Taylor K, Rowlands
M, Ruddle R, Henley A, de Haven Brandon A, Valenti M, Davies TG,
Fazal L, Seavers L, Raynaud FI, Eccles SA, Aherne GW,
Garrett MD, Collins I. 2010, Discovery of 4-amino-1-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)piperidine-4-carboxamides
As Selective, Orally Active Inhibitors of Protein Kinase B (Akt), J Med
Chem. 53 (5), 2239-2249. (http://dx.doi.org/10.1021/jm901788j)
5. Yap TA, Yan L, Patnaik A, Fearen I, Olmos D,
Papadopoulos K, Baird RD, Delgado L, Taylor A, Lupinacci L, Riisnaes
R, Pope LL, Heaton SP, Thomas G, Garrett MD,
Sullivan DM, de Bono JS, Tolcher AW. 2011, First-in-Man
Clinical Trial of the Oral Pan-AKT Inhibitor MK-2206 in Patients With
Advanced Solid Tumors, J Clin Oncol. 29 (35), 4688-4695. (http://dx.doi.org/10.1200/JCO.2011.35.5263)
Quality Indicators
Selected research grant support
1. Workman — "Cancer Research Campaign Centre for Cancer Therapeutics",
2001-2006, £22.5M, programme grant which included the PKB project
2. Workman — "Cancer Research UK Centre for Cancer Therapeutics",
2006-2011, £30.5M, programme grant which included the PKB project
3. Garrett — "PK/PD Analysis for AT13148 Development", Cancer Research UK
Drug Development Office, 2012-2014, £157k; [additional funding related to
AT13148 from CRUK DDO: 2009-2013, total £34k]
Prizes
1. American Association of Cancer Research Team Science Award 2012 for
the team's (involving 16 ICR Faculty members) tremendous impact in
preclinical and clinical studies relating to cancer therapeutics, which
included the highly promising inhibitors of PKB/AKT. (http://www.aacr.org/home/scientists/scientific-achievement-awards/scientific-award-winners/team-science-award-.aspx)
Details of the impact
The ICR has made a major impact on the international search for
inhibitors of PKB, a key signalling enzyme and a major target for the
development of cancer therapeutics. This is a significant impact in
enabling a number of pharmaceutical companies to advance their research
programmes for the development and commercialisation of novel drugs.
Currently seven novel PKB inhibitors are in clinical trial
(ClinicalTrials.gov), two of which are from the joint ICR and Astex PKB
drug discovery programme.
Impacts on health
Two distinct drugs discovered by ICR and Astex Pharmaceuticals are
progressing through clinical trials in the UK and overseas; patients
are benefiting by being able to participate in these trials.
ICR has discovered two series of PKB inhibitors in a collaborative
research programme with Astex Pharmaceuticals. As a result, one series was
licensed in a commercial agreement with AstraZeneca and the lead drug,
AZD5363, is currently undergoing clinical trials at RM, The Christie
(Manchester), the NKI ( Netherlands) and in Japan, involving a total of
over 400 patients (ClinicalTrials.gov Identifiers: NCT01226316,
NCT01353781, NCT01625286, NCT01692262, NCT01895946) [1]. The ICR has led
on the first trial of AZD5363 and Dr Udai Banerji (ICR Faculty, from 2007)
gave an oral presentation at AACR 2013, summarising its exciting potential
in the clinic and reporting for the first time clinical responses in
patients whose tumours had PIK3CA and AKT mutations. This
highlights the fact that this drug has potential applications in a wide
range of solid tumours including breast and gynaecological cancers.
Results of the first Phase I clinical trial of AZD5363 have reported both
partial responses and stable disease in patients harbouring mutations in
PIK3CA or AKT1. This therefore identifies these mutations as potential
predictive biomarkers of response for AZD5363. The clinical development
candidate from the second series, AT13148, which is being developed by
Astex Pharmaceuticals, has biological properties distinct from other PKB
inhibitors and could be useful in a different patient group. This drug is
also in clinical trial at RM (ClinicalTrials.gov Identifier: NCT01585701,
estimated enrolment 40 patients) [2].
Worldwide, clinical trials of PKB inhibitors are being facilitated
by the ICR's work to define useful biomarkers and make protocols
generally available.
The ICR was a key site in the first clinical studies of the Merck
inhibitor MK-2206 (Research Ref 5 above) (ClinicalTrials.gov Identifier:
NCT00670488) through its identification of clinical pharmacodynamic (PD)
biomarkers to monitor PKB inhibition, thus facilitating all PKB programmes
worldwide. In some cases these PD markers also have utility in trials of
other drugs, such as PI3K inhibitors. Protocols have been made available
for these biomarker assays. Companies that have licensed the protocols
(for a fee) include Quintiles and Boehringer Ingelheim. So far, six
international pharmaceutical companies have cited this key publication
(Research Ref 5 above) in work describing their PKB inhibitor programmes
(data from Web of Science) [3, 4].
Impacts on commerce
Two distinct drugs discovered by ICR and Astex Pharmaceuticals are
being commercially developed.
The drugs AZD5363 and AT13148, derived from chemical series discovered by
the ICR and Astex Pharmaceuticals, are being developed by AstraZeneca and
Astex Pharmaceuticals, respectively. Both are in clinical trial. This has
a commercial benefit to both these companies by adding to their
development pipeline and therefore increasing shareholder value.
Results of the first Phase I clinical trial of AZD5363 have reported
partial responses in patients harbouring mutations in PIK3CA or AKT1.
This highlights the fact that these drugs have potential single agent
activity in solid tumours. Multiple clinical trials of combinations of
AZD5363 are currently ongoing and in planning to maximize its potential in
a wide range of cancers.
As stated above, the international PKB drug discovery effort has been
facilitated by the ICR's structural biology and pharmacodynamic biomarker
studies. In addition to the benefit to patients, this has also had
commercial impact, as a number of pharmaceutical companies have added PKB
programmes to their pipelines. For example, since 2008 GSK has made a
major investment into developing PKB inhibitors as novel therapeutics. Its
lead product, GSK2110183, progressed into Phase II clinical trials in
2009.
Industry is investing in pre-clinical research and clinical
research to develop PKB inhibitors in the UK (including at the ICR and
RM) and overseas.
AstraZeneca and Astex Pharmaceuticals are investing in the clinical
research of AZD5363 and AT13148 respectively by conducting clinical
trials. These drugs are based on the chemical series discovered by the
ICR. Companies such as GSK that have cited the ICR's underpinning research
are investing in clinical research worldwide (ClinicalTrials.gov lists
several GSK2110183 clinical trials eg: NCT01428492, NCT01531894,
NCT01532700 and NCT01653912), and seven novel PKB inhibitors are now being
developed.
Sources to corroborate the impact
[1] http://investor.astx.com/releasedetail.cfm?ReleaseID=663984
[2] http://investor.astx.com/releasedetail.cfm?ReleaseID=663805
[3] Sommer EM et al. 2013, Elevated SGK1 predicts resistance of breast
cancer cells to Akt inhibitors, Biochem J. 452, 499-508. (http://dx.doi.org/10.1042/BJ20130342)
[4] Modur V et al. 2013, Evidence-Based Laboratory Medicine in Oncology
Drug Development: From Biomarkers to Diagnostics, Clin Chem. 59 (1),
102-109.
(http://dx.doi.org/10.1373/clinchem.2012.191072)